Thanks to the generosity of patients participating in research, benefactor funding, and the dedication of Mayo researchers, people managing primary sclerosing cholangitis in the present can look forward to a brighter future.
It’s both a mouthful and a ruthless condition: primary sclerosing cholangitis.
An abnormal liver test is the first sign of trouble for about half of patients. The other half already deal with fatigue, jaundice, itching and abdominal pain from the liver damage. And, for the majority of PSC patients, this is not the only chronic disease they manage. Between 70 and 80 percent of PSC patients also have inflammatory bowel disease, most commonly ulcerative colitis.
PSC is a chronic disease affecting about one in 10,000 people, and having it raises the risk of colon, bile duct, and gallbladder cancers. Based on data collected by the United Network for Organ Sharing, six percent of all liver transplants in the United States are due to PSC despite that condition’s overall rarity. But even a transplant doesn’t always wipe out the disease. Read the rest of the article.
Find more research news on Discovery's Edge.